PARP inhibition in treatment of pancreatic cancer-Reference-Cited by-同舟云学术

PARP inhibition in treatment of pancreatic cancer

Published:2020-09-16 Issue:11 Volume:20 Page:939-945
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Hammel Pascal¹,Zhang Chen¹,Matile Julia¹,Colle Elise¹,Hadj-Naceur Imene¹,Gagaille Marie-Pauline²,Bouattour Mohamed¹,Cros Jérôme³,de Mestier Louis⁴,Lamuraglia Michele¹

Affiliation:

1. Departments of Digestive and Medical Oncology, Hôpital Beaujon (AP-HP, Clichy) and Paris University, France

2. Department of Pharmacy, Hôpital Beaujon (AP-HP, Clichy) and Paris University, France

3. Department of Pathology, Hôpital Beaujon (AP-HP, Clichy) and Paris University, France

4. Department of Gastroenterology and Pancreatology, Hôpital Beaujon (AP-HP, Clichy) and Paris University, France

Funder

funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2020.1820330

Reference64 articles.

1. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

2. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

3. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

4. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs;Cancer Research;2024-01-31

2. Pancreatic Cancer;Biomedical Aspects of Solid Cancers;2024

3. Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07

4. DNA repair pathways in breast cancer: from mechanisms to clinical applications;Breast Cancer Research and Treatment;2023-06-08

5. Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment;Expert Opinion on Therapeutic Targets;2022-11-02